|Bid||91.72 x 900|
|Ask||92.74 x 800|
|Day's Range||87.82 - 93.11|
|52 Week Range||44.85 - 99.52|
|Beta (3Y Monthly)||2.61|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||104.27|
Exact Sciences was in trouble a decade ago. Its stock price was so low, it was in danger of being delisted from Nasdaq. That's when Kevin Conroy joined and helped turn the company around. Exact Sciences Chairman and CEO Kevin Conroy joins Yahoo Finance's Seana Smith.
Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and investors' positions as of the end of the fourth quarter. You can find write-ups about an individual hedge fund's trades on numerous financial news websites. […]
EXACT Sciences Corporation (NASDAQ: EXAS ) shares have risen over 50 percent year-to-date, and Goldman Sachs sees further upside ahead. The Analyst Patrick Donnelly maintained a Buy rating on Exact Sciences ...
Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. But when you hold the right stock for the right time period, the rewards can be truly huge. One such superstar is E...
Exact Sciences Corp NASDAQ:EXASView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is moderate for EXAS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding EXAS are favorable with net inflows of $114.36 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
MADISON, Wis., Apr. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company plans to release its first-quarter 2019 financial results after the close of the U.S. financial markets on Apr. 30, 2019. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. A replay of the conference call will be available by calling 800-585-8367 domestically or 416-621-4642 internationally.
Investment scams are nothing new. But since the dot-com bust of 2000, most investors have been able to spot the most egregious, misleading of corporate pitches.That's what's made the Theranos debacle such a shock. The blood-testing company looked, felt and sounded like the real deal. CEO Elizabeth Holmes seemed remarkably credible too… credible enough that insurers, pharmacies and grocery stores were all willing to partner with Theranos.The whole thing, however, was an incredible scam. The company's blood-based tests, as it turns out, couldn't do what Holmes had for years claimed they could. Their results were misleading at best and dangerously wrong at worst. Theranos is no defunct.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNot surprisingly, Theranos' scandal has made investors skeptical of many similar diagnostic companies. * 7 Reasons to Buy Housing Stocks in 2019 That need not be the case, however. Theranos was the exception to the norm rather than the norm. There are many legitimate diagnostic companies, and one area that's seeing a huge boom is genomic testing. Genomic testing stocks belong to companies that look a person's -- or cancer's -- specific gene sequence in order to diagnose and treat patients. Here's a look at eight of the best of them. Exact Sciences (EXAS)Source: Shutterstock Exact Sciences (NASDAQ:EXAS) is committed to treating cancer by spotting it before it forms. Through its partnership with the Mayo Clinic, the company has developed diagnostic tools that can spot concerning colon cancer biomarkers from even the smallest DNA samples, identifying how vulnerable a particular person may be to cancer. In fact, you may be more familiar with the company than you realize. Exact Sciences is the name behind Cologuard, the colon-cancer screener that can be used at home rather than at a doctor's office of medical lab.Exact Sciences isn't yet profitable, but it's also not stopping at colon cancer. It's also working on screening tests that could identify liver, lung, breast and pancreatic cancers. More marketable tests means more revenue, which pushes the company closer to profitability. Genomic Health (GHDX)Source: Shutterstock Genomic Health (NASDAQ:GHDX) is arguably one of the quintessential genomic testing stocks. The company's Oncotype IQ tests allow doctors and caregivers to look at the specific nuances of a particular patient's cancer and tailor a specific treatment plan for that individual. More important, it works. And the medical community believes in what the company brings to the table.At this week's Gallen International Breast Cancer Conference, Dr. Joseph Gligorov of the Breast Cancer Expert Center at the APHP-Tenon Hospital in Paris commented:"The practice-changing precision made possible by such a test can lead to improved quality of care and survival among breast cancer patients, as well as reduced waste of healthcare resources by directing chemotherapy only to patients who have a high likelihood of deriving substantial benefit." * 3 Gold Stocks That Should Glitter With Rising Gold Prices So far the Oncotype battery is limited to breast, prostate and colon cancers, but more forms of cancer are on the radar. In the meantime, Genomic Health continues to refine its existing, proven tests. Sarepta Therapeutics (SRPT)Source: Shutterstock Sarepta Therapeutics (NASDAQ:SRPT) isn't exactly at home in a list of genomic testing stocks in that it's actually the developer of a treatment for Duchenne muscular dystrophy. Its therapy is gene-based, however, making the company more than relevant to investors that believe in the power of gene therapy. Its core product is Exondys 51 -- an injection that can cause a cell to 'skip' a faulty exon in RNA when replicating itself, restoring dystrophin production to functional levels. Dystrophin is a protein needed to make muscles function properly.Sarepta isn't stopping there, however. It's also working on an LGMD gene therapy that Janney analyst Yun Zhong has high hopes for. Zhong, in fact, believes Sarepta could double the size of the exon-skipping market by 2020. Crispr Therapeutics (CRSP)Source: Shutterstock Fans and followers of biotech developments have almost certainly heard the term 'CRISPR,' which is short for 'clustered regularly interspaced short palindromic repeats.' It's a family of DNA sequences that allow researchers and drug developers to manipulate longer spans of genetic material rather than repair one small segment of genetic material. Crispr Therapeutics (NASDAQ:CRSP) is one of the names that helped usher in the new way of thinking about gene-editing. Like Sarepta Therapeutics, it's arguably a little out of place in a look at genomic testing stocks to consider. But the biopharma outfit represents the best of the potential the industry sees for itself as it learns more about how DNA works (and doesn't work). * 10 Tech Stocks With Key Products That Face an Uncertain Future Crispr Therapeutics has already put the idea to good use too. Its pipeline includes treatments for hemoglobinopathies, some cancers, diabetes and other genetic diseases. InVitae (NVTA)InVitae (NYSE:NVTA) isn't exactly a household name, but perhaps someday it will be. The company makes a variety of genomics-based tests that help patients pinpoint potential problem ranging from heart trouble to cancer risks to neurological issues, just to name a few.And customers are buying them up, in spades. Last quarter's top line was up a whopping 117% year-over-year, with unit sales growing more than 100%.InVitae is still logging losses, but they're shrinking, and they're improving at an increasingly faster clip. This year's projected loss of $1.78 per share is only modestly better than last year's loss of $1.94 per share of NVTA stock. But, that loss is expected to be whittled down to only $1.15 per share next year -- on strong double-digit sales growth.InVitae is arguably the name investors are errantly looking past. Illumina (ILMN)Source: Flickr Whereas InVitae is the red-hot name few people have heard of, Illumina (NASDAQ:ILMN) is one of the genomic testing stocks most investors have heard of. The $45 billion behemoth is not only the name that's impossible to avoid, it's been largely deemed as the industry's standard-bearer. Illumina, in simplest terms, makes gene-sequencing and array technologies that can be utilized by drug developers or diagnostic companies. It's powering the genomic-testing market forward by empowering others. * Is This Overlooked Marijuana Stock a Buy? It's also, unlike most of its genomic-focused peers, profitable. Last quarter's revenue may have only grown 11% year-over-year. But, that top line of $867 million translated into earnings of $1.32 per share. For the full year, Illumina banked a profit of $5.72, which is expected to swell to $6.53 this year and $7.50 per share next year. Veracyte (VCYT)Source: Shutterstock Veracyte (NASDAQ:VCYT) currently offers three genomic tests. Afirma helps pin down thyroid cancers, Percepta helps doctors take aim at lung cancer and Envisia aids in the diagnosis of idiopathic pulmonary fibrosis. Like InVitae, Veracyte isn't yet profitable. But, also like InVitae, strong sales growth is quickly chipping away at its losses. Last year's loss of 62 cents per share is expected to shrink to a loss of only 41 cents per share of VCYT stock this year, and shrink to only 23 cents per share next year.Real profits are in sight, even if only on the distant horizon. Myriad Genetics (MYGN)Source: Shutterstock Finally, add Myriad Genetics (NASDAQ:MYGN) to a list of genomic testing stocks to consider. Myriad Genetics appropriately offers a myriad of genomic tests that can help patients and doctors look for genetic markers for everything ranging from breast cancer to depression to arthritis and more.And, like Illumina, Myriad Genetics is profitable. The $2.5 billion outfit turned $217 million worth of revenue last quarter, up 15%, into income of $6.1 million. Its hereditary cancer screener led the way. * The 7 Best Penny Stocks to Buy Growth appears to be in the cards too… perhaps much more than most investors fully appreciate. The medical community is fast-becoming a believer in the power of genetic testing, with the American Society of Breast Surgeons now recommending genetic testing for all breast cancer patients. Meanwhile, Medicare now covers Myriad's myPath(r) Melanoma test.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley.Compare Brokers The post 8 Genomic Testing Stocks That Can Ease the Sting of Theranos appeared first on InvestorPlace.
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
Sebelius is currently CEO of Lawrence, Kansas-based consulting firm Sebelius Resources and is a director at biopharmaceutical companies Dermira, Inc. and Myovant Sciences.
MADISON, Wis., March 19, 2019 /PRNewswire/ -- Kathleen Sebelius, the 21st Secretary of the U.S. Department of Health and Human Services (HHS) from April 2009 to June 2014 and governor of Kansas from 2003 to 2009, joined the Board of Directors of Exact Sciences Corp. (EXAS), a leader in detecting cancer at its earliest, most treatable stages. Based in Madison, Wisconsin, Exact Sciences delivers life-changing innovations in earlier cancer detection and guidance to give people the confidence to make more effective decisions." alt="Kathleen Sebelius, the 21st Secretary of the U.S. Department of Health and Human Services from April 2009 to June 2014 and governor of Kansas from 2003 to 2009, joined the Board of Directors of Exact Sciences Corp. (EXAS) in March 2019.
Active mutual funds get a bad rap. Although, some of that criticism is well deserved. The truth is most active managers fail to beat their benchmarks and chronically underperform. Because of this, many investors have turned to index investing and ETFs to get their market fix.The reason for so much indexing love, and perhaps the cause of why active mutual funds tend to fail, comes down to cost.Active funds generally cost more than their cheap indexing rivals. Those higher costs are a hurdle that managers must clear before they can tack on any gains. Think about it. An active mutual fund with an expense ratio of 1.25% needs to make that 1.25% first, before it can chase its benchmark. With ETFs charging just 0.03% these days, the ball is in their court.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut here's the thing -- not all active mutual funds are bad. In fact, many can and do clear their higher fee hurdles, offer higher active shares and actually *gasp* beat their beat their benchmarks over time. It's here that investors can get higher returns. Adding a smattering of these active funds to a cheap indexed core portfolio can do wonders. * The 10 Best Stocks to Buy for the Bull Market's Anniversary With that, here are five active mutual funds worthy of their expenses.Source: Shutterstock T. Rowe Price QM U.S. Small-Cap Growth Equity (PRDSX)Expense Ratio: 0.79% or $79 per $10,000 invested. Minimum Investment: $2,500One of the best places to find active mutual funds worth owning is in the small- and mid-cap spaces. In this market cap size, there's more chance to values and great growth stories as Wall Street analysts tend to ignore smaller stocks. And that's just what the T. Rowe Price QM U.S. Small-Cap Growth Equity (MUTF:PRDSX) has been doing since the late 1990s. It looks like one of the best funds in its niche.Fund manager Sudhir Nanda combs through the broader small-cap world by using screens tied to valuation, quality and momentum. Those stocks that meet the standards are included in the portfolio's holdings. Right now, that's 300 stocks, including EXACT Sciences Corporation (NASDAQ:EXAS) and Fair Isaac (NASDAQ:FICO). However, no stock makes up more than around 1.25% of PRDSX's portfolio.The best part is that Nanda and his screens have made PRDSX a top performer.Since 2006 when Nanda became the head manager, PRDSX has managed to beat the S&P 500 by an average 2.7 percentage points a year. Moreover, when looking at its benchmark- the MSCI US Small Cap Growth Index- PRDSX has beaten it over the one-, three-, five- and 10-year periods. And pretty significantly at that.Nanda and his team at PRDSX are clearly adding value for investors and are worth the active mutual funds' 0.79% expense ratio. Fidelity Focused Stock (FTQGX)Expense Ratio: 0.82% Minimum Investment: NoneOne of the best parts about index investing is the diversification involved. So, you want your active fund to perform differently than an index, it can't look like an index. One of the other great ways to beat the market is by concentrating your picks. So-called high-conviction funds only hold a handful of stocks that the managers believe will provide great returns. Instead of 500 stocks, you only get 40. And in that, you get better returns.The Fidelity Focused Stock (MUTF:FTQGX) is one of the best funds at turning concentrated bets into bigger gains.As the name implies, FTQGX is focused on a few stocks. In this case, the active mutual fund will own between 30 and 80 different names. These can be either growth or value stocks that the managers think will outperform over the longer haul. Lately, the active mutual fund's focus has been on growth names, holding only 38 stocks. Healthcare and technology stocks dominate the mutual fund's top holdings. These include Amazon (NASDAQ:AMZN) and AstraZeneca (NYSE:AZN).The fund's results prove that it's high-conviction strategy is a winner.FTQGX has crushed the S&P 500 over its life. The fund has managed to beat the broader index over the 3-, 5- and 10-year periods. Perhaps the biggest win for the mutual fund came last year. As the S&P lost money, the Fidelity Focused Stock mutual fund managed to produce a positive 5.32% return. * 7 Top Stocks to Buy From Goldman Sachs' Secret Portfolio When it comes to active mutual funds, FTQGX is one of the best funds to buy.Source: Shutterstock Vanguard International Growth Fund Investor Shares (VWIGX)Expense Ratio: 0.45% Minimum Investment: $3,000Vanguard is the king of indexing. But the asset manager is pretty good when it comes to active mutual funds as well. A prime example is the Vanguard International Growth Fund Investor Shares (MUTF:VWIGX).International stocks have been a mixed bag since the recession. Like U.S. stocks in the previous decade -- marked by the dot com crash and great recession -- international equities are nearing a so-called lost decade of performance. Indexing in the stocks of Europe, Japan and other developed markets would have netted you basically nothing. Active managers, however, have done much better. VWIGX over the past 10 years, managed to return an average annual 9.52%. That's nearly double its benchmark -- the MSCI World ex-USA Index.VWIGX's excess return comes from its strategy.The fund is dually managed by Baillie Gifford Overseas and Schroder Investment Management at roughly a 60/40 spilt. Baillie Gifford runs a more traditional growth sleeve for its assets. This means paying for stocks that are rapidly growing sales. This has it diving head-first into emerging markets and international tech firms. Schroder's is more of value seeker and uses growth-at-a-reasonable price, or GARP, investing strategy to find bargains. The combination provides fast growth with some stability. That allows for less volatility and overall better returns.And with a Vanguard-low expense ratio, investors are able to keep more of those returns -- even for this actively managed mutual fund.Source: Shutterstock Metropolitan West Total Return Bond (MWTRX)Expense Ratio: 0.67% Minimum Investment: $5,000Bonds and fixed-income investments tend to be another area that active mutual funds can outperform their indexes. That's because many bond indices are rigid in their construction and/or are weighted on the amount of debt. Total return or go-anywhere bond funds allow their mangers to buy what they view is a best bet at the time. Because of that, top active managers in the fixed income space can and do earn returns above their benchmark indexes.That includes the Metropolitan West Total Return Bond (MUTF:MWTRX).The $71 billion behemoth is surprisingly nimble for a bond fund and can really go anywhere to find a good total return -- that is price appreciation and dividends. According to its mandate, the mangers at MWTRX can own corporate bonds, collateralized debt obligations, mortgage-related and asset-backed securities, bank loans, money-market securities, swaps, futures, municipal securities, options, credit default swaps, private placements and restricted securities. And it doesn't matter if they have interest rates that are fixed, variable or floating. It really can own it all.And owning it all has been a great strategy. * 7 Dow Jones Stocks to Buy MWTRX has managed to crush its benchmark -- the Bloomberg Barclays U.S. Aggregate Bond Index- by a mile. Over the last 10-years, the active mutual fund has returned 5.51% annualized. This is versus just a 3.48% annualized return for the index. No wonder why the fund has a four-star rating and a Gold recommendation from Morningstar.Source: Studio Incendo via Flickr (Modified) Matthews Pacific Tiger Fund (MAPTX)Expense Ratio: 1.08% Minimum Investment: $2,500Emerging markets hold plenty of promise and those in Asia are particularly primed for growth. However, how do you know which is a good nation or bad, or which stocks can capitalize the best to take advantage of the potential. Separating the wheat from the chaff takes an active touch and a real boots on the ground approach.That's exactly what the Matthews Pacific Tiger Fund (MUTF:MAPTX) does.Matthews Asia only does Asian-focused mutual funds and separate managed accounts. This expertise has allowed the firm to before better than many of its benchmarks and indexes. This includes MAPTX -- one of its flagship funds.MAPTX bets on stocks in countries and markets in Asia, including developed, emerging, and frontier countries but excluding Japan. However, the bulk of the fund's holdings lie within developing and emerging markets. Sure, China is included … but so is Thailand, Malaysia and Indonesia. This different concentration as well as the fact that the fund only holds about 60 stocks has allowed MAPTX beat its benchmark -- the MSCI All Country Asia ex Japan Index -- over the long haul. Over the last 5- and 10-year periods, MAPTX has beaten the index by roughly 1.5 percentage points per year. Since its inception in 1994, it's more than doubled its performance.Clearly, Matthews has the winning formula in its specialty and has managed to clear its expense ratio hurdle with ease.At the time of writing, Aaron Levitt did not have a position in any of the active mutual funds mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy Under 15x Earnings * 7 Dark Horse Stocks That Deserve Your Attention in 2019 * 5 Disruptive Technologies That Are Moving Too Fast Compare Brokers The post 5 Active Mutual Funds Worth Their Expenses appeared first on InvestorPlace.
EXAS has made higher lows and higher highs. The pattern of volume below the price chart is not inspiring. Yes, volume was strong in April through August, but since then it has been boring and the On-Balance-Volume (OBV) line has not made much upside progress since September.
MADISON, Wis., March 6, 2019 /PRNewswire/ -- Exact Sciences Corporation (EXAS) announced today that it has priced its underwritten public offering of 0.3750% convertible senior notes due 2027 (the "Notes") and upsized the offering from $600 million to $650 million aggregate principal amount. The Company has granted the underwriter a 30-day option to purchase up to an additional $97.5 million aggregate principal amount of the Notes solely to cover over-allotments, if any. The Notes will be senior unsecured obligations of the Company and will bear interest at a rate of 0.3750% per annum. Interest on the Notes will be payable semi-annually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The Notes will be convertible into cash, shares of the Company's common stock (and, if applicable, cash in lieu of any fractional share), or a combination thereof, at the Company's election. The initial conversion rate will be 8.9554 shares of the Company's common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $111.6645 per share.
MADISON, Wis., March 5, 2019 /PRNewswire/ -- Exact Sciences Corporation (EXAS) (the "Company") today announced an underwritten public offering of $600 million aggregate principal amount of convertible senior notes due 2027 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $90.0 million aggregate principal amount of the Notes. Concurrently with this offering, in separate transactions, the Company also expects to enter into agreements with certain holders of its 1.0% Convertible Senior Notes due in January 2025 (the "2025 Notes") to exchange an aggregate of approximately 50% of the outstanding principal amount of such notes for consideration consisting of cash, shares of the Company's common stock or a combination thereof.
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
MADISON, Wis., March 1, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 27) Abbott Laboratories (NYSE: ABT ) argenx SE – ADR (NASDAQ: ...